FY2024 Earnings Forecast for MaxCyte Issued By William Blair

MaxCyte, Inc. (NASDAQ:MXCT) – Equities research analysts at William Blair boosted their FY2024 earnings per share (EPS) estimates for shares of MaxCyte in a note issued to investors on Thursday, November 7th. William Blair analyst M. Larew now expects that the company will earn ($0.43) per share for the year, up from their previous forecast of ($0.47). The consensus estimate for MaxCyte’s current full-year earnings is ($0.43) per share. William Blair also issued estimates for MaxCyte’s Q4 2024 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.46) EPS.

MaxCyte (NASDAQ:MXCT) last issued its earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The business had revenue of $8.16 million during the quarter, compared to analysts’ expectations of $7.50 million. During the same period in the prior year, the firm posted ($0.11) EPS.

MaxCyte Trading Down 1.1 %

Shares of MXCT opened at $3.54 on Monday. MaxCyte has a 1 year low of $3.23 and a 1 year high of $5.55. The stock has a 50 day simple moving average of $3.82 and a 200-day simple moving average of $4.18. The stock has a market cap of $373.41 million, a PE ratio of -10.53 and a beta of 1.40.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC bought a new position in MaxCyte in the 3rd quarter valued at $51,000. Royce & Associates LP boosted its position in shares of MaxCyte by 59.8% in the 3rd quarter. Royce & Associates LP now owns 323,924 shares of the company’s stock worth $1,260,000 after purchasing an additional 121,272 shares during the last quarter. River Global Investors LLP boosted its position in shares of MaxCyte by 4.7% in the 3rd quarter. River Global Investors LLP now owns 2,062,562 shares of the company’s stock worth $8,034,000 after purchasing an additional 93,340 shares during the last quarter. Roubaix Capital LLC boosted its position in shares of MaxCyte by 3.1% in the 3rd quarter. Roubaix Capital LLC now owns 427,515 shares of the company’s stock worth $1,663,000 after purchasing an additional 12,697 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of MaxCyte by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock worth $79,000 after purchasing an additional 7,930 shares during the last quarter. 68.81% of the stock is currently owned by institutional investors.

Insider Activity at MaxCyte

In related news, Director Stanley C. Erck sold 21,607 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the completion of the sale, the director now directly owns 269,118 shares of the company’s stock, valued at $998,427.78. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other MaxCyte news, Director Stanley C. Erck sold 21,607 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total value of $80,161.97. Following the transaction, the director now directly owns 269,118 shares in the company, valued at approximately $998,427.78. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stanley C. Erck sold 29,767 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.97, for a total value of $118,174.99. Following the completion of the transaction, the director now owns 269,118 shares in the company, valued at $1,068,398.46. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 60,374 shares of company stock valued at $233,797 in the last three months. Corporate insiders own 3.00% of the company’s stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.